Scaffold Searching of FDA and EMA-Approved Drugs Identifies Lead Candidates for Drug Repurposing in Alzheimer’s Disease
Clinical trials of novel therapeutics for Alzheimer’s Disease (AD) have consumed a significant amount of time and resources with largely negative results. Repurposing drugs already approved by the Food and Drug Administration (FDA), European Medicines Agency (EMA), or Worldwide for another indicatio...
Үндсэн зохиолчид: | Sergey Shityakov, Ekaterina V. Skorb, Carola Y. Förster, Thomas Dandekar |
---|---|
Формат: | Өгүүллэг |
Хэл сонгох: | English |
Хэвлэсэн: |
Frontiers Media S.A.
2021-10-01
|
Цуврал: | Frontiers in Chemistry |
Нөхцлүүд: | |
Онлайн хандалт: | https://www.frontiersin.org/articles/10.3389/fchem.2021.736509/full |
Ижил төстэй зүйлс
Ижил төстэй зүйлс
-
In silico repurposing of FDA-approved drugs as multi-target inhibitors of glioblastoma
-н: Ridwan Abiodun Salaam, зэрэг
Хэвлэсэн: (2025-03-01) -
A Transcriptomics-Based Bioinformatics Approach for Identification and In Vitro Screening of FDA-Approved Drugs for Repurposing against Dengue Virus-2
-н: Madhura Punekar, зэрэг
Хэвлэсэн: (2022-09-01) -
Editorial: Adopting drug repurposing to overcome drug resistance in cancer
-н: Eswar Shankar, зэрэг
Хэвлэсэн: (2023-04-01) -
Network-based drug repurposing for potential stroke therapy
-н: Qihui Wu, зэрэг
Хэвлэсэн: (2023-01-01) -
Approved drugs successfully repurposed against Leishmania based on machine learning predictions
-н: Rafeh Oualha, зэрэг
Хэвлэсэн: (2024-09-01)